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ABSTRACT
Objectives To determine the feasibility of conducting a 
randomised trial of the effectiveness of cranberry extract 
in reducing antibiotic use by women with symptoms of 
acute, uncomplicated urinary tract infection (UTI).
Design Open- label feasibility randomised parallel group 
trial.
Setting Four general practices in Oxfordshire.
Participants Women aged 18 years and above 
presenting to general practice with symptoms of acute, 
uncomplicated UTI.
Interventions Women were randomly assigned using 
Research Electronic Data Capture in a 1:1:1 ratio to: 
(1) immediate antibiotics alone (n=15); (2) immediate 
antibiotics and immediate cranberry capsules for up 
to 7 days (n=15); or (3) immediate cranberry capsules 
and delayed antibiotics for self- initiation in case of non- 
improvement or worsening of symptoms (n=16).
Primary and secondary outcome measures The 
primary outcome measures were: rate of recruitment 
of participants; numbers lost to follow- up; proportion 
of electronic diaries completed by participants; and 
acceptability of the intervention and study procedures to 
participants and recruiters. Secondary outcomes included 
an exploration of differences in symptom burden and 
antibiotic use between groups.
Results Four general practitioner practices (100%) were 
opened and recruited participants between 1 July and 2 
December 2019, with nine study participants recruited per 
month on average. 68.7% (46/67) of eligible participants 
were randomised (target 45) with a mean age of 48.4 
years (SD 19.9, range 18–81). 89.1% (41/46) of diaries 
contained some participant entered data and 69.6% 
(32/46) were fully complete. Three participants (6.5%) 
were lost to follow- up and two (4.4%) withdrew. Of women 
randomly assigned to take antibiotics alone (controls), 
one- third of respondents reported consuming cranberry 
products (33.3%, 4/12). There were no serious adverse 
events.
Conclusions It appears feasible to conduct a randomised 
trial of the use of cranberry extract in the treatment of 
acute, uncomplicated UTI in general practice.
Trial registration number ISRCTN Registry (ID: 
10399299).
INTRODUCTION
In light of rising levels of antimicrobial resis-
tance, there has been growing interest in the 
use of non- antibiotic treatments for common 
bacterial infections, such as urinary tract 
infections (UTIs). UTIs are one of the most 
common bacterial infections seen in primary 
care,1 and are nearly always treated with anti-
biotics.2 Trials have evaluated non- antibiotic 
treatments for acute uncomplicated UTIs 
in primary care,3–7 and use of ibuprofen 
has enabled some women to manage UTIs 
without taking antibiotics, although with a 
greater symptom burden compared with anti-
biotic treatment, and more cases of pyelone-
phritis.3 6 7
Cranberry has been extensively evalu-
ated as a preventative agent for UTIs, with 
mixed results. Up to 27% of women report 
using cranberry to help treat the symptoms 
of an acute UTI.8 Despite this, there is a lack 
of trials assessing whether cranberry can be 
used to treat the symptoms of acute UTIs, 
alone, or in combination with antibiotics. 
There are some mechanistic data to support 
this approach; urine collected within 6 
hours of consumption of cranberry powder 
containing standardised amounts of proan-
thocyanidins (PAC) has been shown to exert 
an anti- adhesion effect against Escherichia coli 
in vitro, in a dose- dependent fashion.9 PAC 
Strengths and limitations of this study
 ► This feasibility trial addresses a novel use of cran-
berry extract in the treatment of acute, rather than 
prevention of recurrent, urinary tract infection.
 ► A pragmatic, open- label randomised trial design 
was employed.
 ► In keeping with pragmatic trials, no placebo control 
was used.
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with type A linkages, or the breakdown products after 
digestion in the gut, is believed to be the active ingredient 
in cranberry.10
The primary objective of this feasibility trial was 
therefore to determine the feasibility of conducting a 
randomised clinical trial to determine the effectiveness 
of cranberry extract in reducing antibiotic use by women 
with symptoms of acute, uncomplicated UTI in general 
practice.
METHODS
Trial design and participants
This was an open- label, pragmatic, feasibility trial with 
randomisation in a 1:1:1 ratio between treatment groups 
in UK primary care. The eligibility criteria have been 
described in detail elsewhere.11 In brief, women aged 
18 years and above with symptoms of acute, uncompli-
cated UTI, to whom their healthcare practitioner would 
normally give a prescription for immediate antibiotics, 
and presenting to one of four participating general prac-
titioner (GP) practices in Oxfordshire, were eligible. 
Prospective participants had to be prepared to accept 
a delayed antibiotic prescription; that is, an antibiotic 
prescription with advice not to take the antibiotics unless 
their symptoms did not improve, or worsened. Women 
were excluded if they had signs of upper or complicated 
UTI, if they had received antibiotics in the preceding 7 
days, if they had a symptom duration of 7 days or more, 
or if they regularly consumed cranberry products on 5 or 
more days per week.
Participants were emailed a link to an electronic 
symptom diary and were asked to complete it daily for 2 
weeks. They were asked to rate a number of symptoms on 
a scale of 0–50, and to record any UTI treatments (study 
interventions or otherwise) that they were taking. The list 
of symptoms in the daily diary has been published with 
the feasibility trial protocol.11 The scale used was an adap-
tation of a validated 7- point Likert scale developed by 
Watson et al12:
 ► 0=normal/not affected.
 ► 1–9=very little problem.
 ► 10–19=slight problem.
 ► 20–29=moderately bad.
 ► 30–39=bad.
 ► 40–49=very bad.
 ► 50=as bad as it could be.
We used this wider scale as part of the feasibility testing 
to see whether participants liked having more rating 
options. We also wondered whether the wider scale 
might enable better detection of within- participant and 
between- participant rating variation. A follow- up phone 
call took place at 2 weeks to encourage diary completion 
and obtain a minimum data set from participants whose 
diaries were incomplete. Women were invited for inter-
view at a later date if they had provided consent at the 
point of trial recruitment to receive information about 
the interview study. A notes review took place at 4 weeks 
to record any clinical contacts that were believed to be 
related to the original UTI episode, as well as the urine 
culture result.
Adverse event data were collected through symptom 
diary entries, through participant reports at the 2- week 
follow- up call and through notes reviews.
Interventions
Women in group 1 (control) received a prescription for 
first- line immediate antibiotics alone. In keeping with 
pragmatic trial design, the antibiotic prescribed and the 
duration was at the discretion of the recruiting clinician. 
In the UK, the usual recommended first- line treatment 
for acute uncomplicated UTI is a 3- day course of nitrofu-
rantoin.13 Women assigned to group 2 received an imme-
diate prescription for first- line antibiotics and a course of 
cranberry capsules to be taken alongside antibiotics until 
symptom resolution, or up to a maximum of 7 days. The 
cranberry capsules (Redicran) were supplied free to the 
study by Indena SpA. This company had no other involve-
ment with the trial. Each capsule contained 18 mg of 
PAC. Women were advised to take two capsules two times 
per day at 12- hour intervals, making a total of 72 mg of 
PAC daily. Ex- vivo studies suggest that consumption of 72 
mg PAC has anti- adhesion activity against uropathogenic 
E. coli.9 Women in group 3 were advised to take imme-
diate cranberry capsules (Redicran) for up to 7 days. They 
also received a delayed antibiotic prescription to be used 
if their symptoms did not improve within 3–5 days, or if 
their symptoms worsened.
Outcomes
The primary outcomes were feasibility measures,11 namely, 
the rate of recruitment of participants, the number of 
participants lost to follow- up, and the acceptability of 
trial processes and the quality of data capture using elec-
tronic symptom diaries. These data can contribute to 
sample size calculations for an adequately powered trial, 
and additionally increase the chance of such a trial being 
successful. The study was not powered to detect differ-
ences between groups. Nevertheless, secondary outcomes 
included an exploration of between- group differences in 
measures of symptom burden, antibiotic consumption 
and adverse events.11
Although not made explicit in the protocol, a compar-
ison of the time to feeling fully recovered between groups 
was made, as prespecified in the statistical analysis plan. 
These data were already being collected through the elec-
tronic diary, which had received ethical approval. A deci-
sion to conduct an exploratory analysis of the proportion 
of participants experiencing ‘double sickening’ (feeling 
fully recovered and then subsequently feeling unwell 
within 2 weeks of trial enrolment) was made after the 
statistical analysis plan had been completed, but before 
the trial data had been reviewed or analyses commenced. 
The concept of double sickening has been noted in acute 
respiratory illness14; we felt that an exploratory analysis of 
this concept in the context of acute UTI would be novel 
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and useful. A substantial amendment was approved by 
the ethics committee after trial recruitment had started 
to allow the trial team to interview enrolling clinicians to 
the trial, as part of the study’s feasibility assessment.
Sample size and randomisation
A sample size of 45 participants was chosen to enable esti-
mation of a loss- to- follow- up rate of 20% with a CI of 9.6% 
to 34.6%.11 Sample sizes of between 2415 and 5016 have 
been suggested for pilot studies.
The randomisation sequence was generated using Stata 
V.15.1 (StataCorp, College Station, Texas, USA) by a 
statistician at the Nuffield Department of Primary Care 
Health Sciences, University of Oxford, using computer- 
generated block randomisation with variable block size. 
The sequence was password protected and accessible 
only by the statistician. Participants were randomised by 
recruiting clinicians through the click of a button on the 
electronic trial registration page, which was created using 
Research Electronic Data Capture.
Statistical methods
Unless otherwise stated, primary outcomes are presented 
as proportions and percentages for each trial group and 
for the entire trial population. Participants in group 2 
and group 3 were compared separately with participants 
in group 1 (the control group).
The number of antibiotic courses (or part thereof) 
consumed by participants in each group at 2 weeks and 
4 weeks was compared using Poisson regression and 
reported using incidence rate ratios. The difference in 
the duration of symptoms rated moderately bad or worse 
between groups was compared using negative bino-
mial regression; incidence rate ratios are reported and 
a Kaplan- Meier graph plotted (online supplemental file 
1). The mean symptom burden scores (from day 2 to 
day 4 inclusive) were compared between groups using 
linear regression, and reported using mean differences. 
The difference in time to feeling fully recovered between 
groups was compared using the Cox proportional- hazards 
model; HRs are presented and a Kaplan- Meier graph was 
plotted (online supplemental file 1). Each estimate was 
adjusted for study site.
A risk ratio and 95% CI was used to estimate the differ-
ence in the proportion of participants consuming a course 
of antibiotics (or part thereof) between groups at 2 weeks 
and 4 weeks, the difference in the proportion of adverse 
events between groups at both 2 weeks and 4 weeks, and 
to compare the proportion of participants in each group 
experiencing double sickening. It was not possible to 
use log binomial regression, as originally planned, to 
compare the proportion of participants consuming anti-
biotics between groups as the model would not converge. 
A risk ratio and 95% CI was used in lieu of Fisher’s exact 
test (as originally planned) to estimate the difference in 
proportion of adverse events between groups in order to 
generate 95% CIs rather than p values. As this study was 
not powered to detect differences between groups, we 
had prespecified that p values would not be reported.
Intention- to- treat analysis was conducted for all analyses 
and estimates are presented with their 95% CIs. Due to 
the small sample size and the fact that this is a feasibility 
study, no subgroup or sensitivity analyses were conducted.
Patient and public involvement
Four patient and public involvement (PPI) contributors 
have been closely involved with the study from the outset, 
two of whom sit on the Trial Steering Committee. During 
trial conception and development, they confirmed that 
the topic chosen was important. They critiqued all public- 
facing trial documentation to ensure that it was free of 
jargon, and their feedback was incorporated. They were 
also involved in the design of the electronic diary, helping 
to ensure that it was user- friendly. PPI contributors unan-
imously felt that the diary would not be onerous for 
participants; and suggested it may make the experience 
of participating in the trial more meaningful, stating “…
completing the symptom diary hooks people in. It makes 
them feel that they are contributing.” The results of the 
study have been shared with PPI contributors, allowing 
them to give their views on ways to explain the findings, 
which have been incorporated into the discussion. PPI 
contributors are also helping to inform the dissemination 
of the study findings.
RESULTS
Baseline data
Baseline information was completed electronically by 
participants upon accessing the electronic diary on day 
1 of enrolment, prior to inputting their day 1 symptom 
ratings. The mean age of participants was 48.3 years 
(range: 18–81 years). The mean age of women in the 
immediate cranberry and delayed antibiotics group 
was lower than the other two groups. Most women had 
experienced a previous UTI (85.4%, 35/41). A total of 
75.6% (31/41) of respondents were expecting antibi-
otics. Sixty- one per cent (25/41) believed that cranberry 
could help their symptoms, while 24.4% (10/41) believed 
that their symptoms could improve without antibiotics 
(table 1).
Primary outcomes
Forty- six women were recruited to the trial, surpassing 
the target of 45 (see figure 1). Of the 21 women who 
were eligible but declined to take part, the most common 
reason for declining was not wishing to be randomised 
to receive delayed antibiotics (42.9%, 9/21). The first 
participant was recruited on 11 July 2019 and the final 
participant was recruited on 2 December 2019, with the 
final follow- up taking place on 30 December 2019. The 
findings of qualitative interviews with 14 trial participants 
and 8 trial recruiters will be presented elsewhere.
A total of 89.1% (41/46) of electronic diaries had some 
data entered by participants, while 69.6% (32/46) of 
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Table 1 Baseline characteristics of participants
Proportion (%), unless otherwise specified
Group 1
(n=15)
Group 2
(n=15)
Group 3
(n=16)
Total
(n=46)
Age in years, mean (SD) (range) 52.4
(21.4)
(18–81)
52.4
(22.4)
(19–81)
40.8
(14.0)
(20–63)
48.3
(19.9)
(18–81)
Previous UTI
  Yes 12/15
(80%)
12/13 (92.3%) 11/13 (84.6%) 35/41 (85.4%)
  No 3/15
(20%)
1/13
(7.7%)
2/13
(15.4%)
6/41
(14.6)
  Missing 0/15 2/15 3/16 5/46
Previous UTI in the past year
  Yes 7/15
(46.7%)
6/13
(46.2%)
6/13 (46.2%) 19/41 (46.3%)
  No 5/15
(33.3%)
6/13
(46.2%)
5/13 (38.5%) 16/41 (39.0%)
  N/A (have never had a previous UTI) 3/15
(20%)
1/13
(7.7%)
2/13 (15.4%) 6/41 (14.6%)
  Missing 0/15 2/15 3/16 5/46
If had a UTI in the past year, number of months 
since last UTI—mean (SD), median (range)
5.4 (4.5),
4 (0–12) n=7
5 (4.2),
5 (0–11) n=5
7 (3.6),
7 (3–12) n=5
5.8 (4.2),
5 (0–12) n=17
  Can’t remember 0/15
(0%)
1/13
(7.7%)
1/12
(8.3%)
2/40
(5%)
  Not applicable 8/15
(53.3%)
7/13
(53.9%)
6/12
(50%)
21/40 (52.5%)
  Missing 0/15 2/15 4/16 6/46
Number of UTIs in the past year
  0 5/15
(33.3%)
7/13
(53.9%)
4/13 (30.8%) 16/41 (39.0%)
  1 3/15
(20%)
2/13
(15.4%)
5/13 (38.5%) 10/41 (24.4%)
  2 2/15
(13.3%)
2/13
(15.4%)
1/13
(7.7%)
5/41 (12.2%)
  3 or more 2/15
(13.3%)
1/13
(7.7%)
1/13
(7.7%)
4/41 (9.8%)
  Not applicable
  (have never had a previous UTI)
3/15
(20%)
1/13
(7.7%)
2/13 (15.4%) 6/41 (14.6%)
  Missing 0/15 2/15 3/16 5/46
Were you expecting antibiotic treatment?
  Yes 13/15
(86.7%)
10/13 (76.9%) 8/13 (61.5%) 31/41 (75.6%)
  No 0/15
(0%)
1/13
(7.7%)
1/13
(7.7%)
2/41 (4.9%)
  Unsure 2/15
(13.3%)
2/13
(15.4%)
4/13 (30.8%) 8/41 (19.5%)
  Missing 0/15 2/15 3/16 5/46
Were you expecting tests/investigations?
  Yes 12/15
(80%)
10/13 (76.9%) 8/13 (61.5%) 30/41 (73.2%)
  No 3/15
(20%)
3/13
(23.1%)
4/13 (30.8%) 10/41 (24.4%)
Continued
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Proportion (%), unless otherwise specified
Group 1
(n=15)
Group 2
(n=15)
Group 3
(n=16)
Total
(n=46)
  Unsure 0/15
(0%)
0/13
(0%)
1/13
(7.7%)
1/41 (2.4%)
  Missing 0/15 2/15 3/16 5/46
Were you expecting advice?
  Yes 12/15
(80%)
11/12 (91.7%) 13/13 (100%) 36/40 (90%)
  No 2/15
(13.3%)
1/12
(8.3%)
0/13
(0%)
3/40 (7.5%)
  Unsure 1/15
(6.7%)
0/12
(0%)
0/13
(0%)
1/40 (2.5%)
  Missing 0/15 3/15 3/16 6/46
Were you expecting something else?
  Yes 0/15
(0%)
1/13
(7.7%)—information 
and prescription (1 
participant)
0/13
(0%)
1/41 (2.4%)
  No 15/15
(100%)
10/13 (76.9%) 11/13 (84.6%) 36/41 (87.8%)
  Unsure 0/15
(0%)
2/13
(15.4%)
2/13 (15.4%) 4/41 (9.8%)
  Missing 0/15 2/15 3/16 5/46
Was your last UTI treated with antibiotics?
  Yes 8/15
(53.3%)
9/13
(69.2%)
10/13 (76.9%) 27/41 (65.9%)
  No 4/15
(26.7%)
3/13
(23.1%)
1/13
(7.7%)
8/41 (19.5%)
  Not applicable 3/15
(20%)
1/13
(7.7%)
2/13 (15.4%) 6/41 (14.6%)
  Missing 0/15 2/15 3/16 5/46
Was your last UTI treated with something other 
than antibiotics?
  Yes 2/15
(13.3%)—
cystitis sachets (2 
participants)
1/13
(7.7%)—cystitis 
sachets (1 
participant)
0/13
(0%)
3/41 (7.3%)
  No 10/15
(66.7%)
11/13 (84.6%) 11/13 (84.6%) 32/41 (78.1%)
  Not applicable 3/15
(20%)
1/13
(7.7%)
2/13 (15.4%) 6/41 (14.6%)
  Missing 0/15 2/15 3/16 5/46
Did you receive no treatment for your last UTI?
  Yes 1/15
(6.7%)
0/13
(0%)
0/13
(0%)
1/41 (2.4%)
  No 11/15
(73.3%)
12/13 (92.3%) 11/13 (84.6%) 34/41 (82.9%)
  Not applicable 3/15
(20%)
1/13
(7.7%)
2/13 (15.4%) 6/41 (14.6%)
  Missing 0/15 2/15 3/16 5/46
Unable to remember how last UTI was treated
Table 1 Continued
Continued
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Proportion (%), unless otherwise specified
Group 1
(n=15)
Group 2
(n=15)
Group 3
(n=16)
Total
(n=46)
  Yes 1/15
(6.7%)
1/13
(7.7%)
1/13
(7.7%)
3/41 (7.3%)
  No 11/15
(73.3%)
11/13 (84.6%) 10/13 (76.9%) 32/41 (78.1%)
  Not applicable 3/15
(20%)
1/13
(7.7%)
2/13 (15.4%) 6/41 (14.6%)
  Missing 0/15 2/15 3/16 5/46
Treatments tried before consulting primary 
care
  Cranberry products
  Yes 2/15
(13.3%)
3/13
(23.1%)
3/13 (23.1%) 8/41 (19.5%)
  No 13/15
(86.7%)
10/13 (76.9%) 10/13 (76.9%) 33/41 (80.5%)
  Missing 0/15 2/15 3/16 5/46
  Other fruit juice
  Yes 1/15
(93.3%)
1/13
(7.7%)
0/13
(0%)
2/41
(4.9%)
  No 14/15
(93.3%)
12/13 (92.3%) 13/13 (100%) 39/41 (95.1%)
  Missing 0/15 2/15 3/16 5/46
  Bicarbonate solution
  Yes 0/15
(0%)
0/13
(0%)
0/13
(0%)
0/41
(0%)
  No 15/15
(100%)
13/13
(100%)
13/13 (100%) 41/41 (100%)
  Missing 0/15 2/15 3/16 5/46
  Sodium/potassium citrate (cystitis sachets)
  Yes 3/15
(20%)
7/13
(53.9%)
1/13
(7.7%)
11/41 (26.8%)
  No 12/15
(80%)
6/13
(46.2%)
12/13 (92.3%) 30/41 (73.2%)
  Missing 0/15 2/15 3/16 5/46
  Uvacin/uva ursi (bearberry)
  Yes 0/15
(0%)
0/13
(0%)
0/13
(0%)
0/41
(0%)
  No 15/15
(100%)
13/13
(100%)
13/13 (100%) 41/41 (100%)
  Missing 0/15 2/15 3/16 5/46
  Pain relief (eg, paracetamol/ibuprofen)
  Yes 6/15
(40%)
7/13
(53.9%)
4/13 (30.8%) 17/41 (41.5%)
  No 9/15
(60%)
6/13
(46.2%)
9/13 (69.2%) 24/41 (58.5%)
  Missing 0/15 2/15 3/16 5/46
  Other treatment used?
Table 1 Continued
Continued
 on M
arch 25, 2021 by guest. P
rotected by copyright.
http://bm
jopen.bm
j.com
/
B
M
J O
pen: first published as 10.1136/bm
jopen-2020-046791 on 22 F
ebruary 2021. D
ow
nloaded from
 
7Gbinigie O, et al. BMJ Open 2021;11:e046791. doi:10.1136/bmjopen-2020-046791
Open access
Proportion (%), unless otherwise specified
Group 1
(n=15)
Group 2
(n=15)
Group 3
(n=16)
Total
(n=46)
  Yes 2/15
(13.3%)—
water (2 
participants)
2/13
(15.4%)—
tea tree in bath (1 
participant);
sachets (1 
participant)
2/13 (15.4%)—
water (2 
participants)
6/41 (14.6%)
  No 13/15
(86.7%)
11/13 (84.6%) 11/13 (84.6%) 35/41 (85.4%)
  Missing 0/15 2/15 3/16 5/46
  None
  Yes 7/15
(46.7%)
2/13
(15.4%)
5/13 (38.5%) 14/41 (34.2%)
  No 8/15
(53.3%)
11/13 (84.6%) 8/13 (61.5%) 27/41 (65.9%)
  Missing 0/15 2/15 3/16 5/46
Number of days symptomatic
  0 1/15
(6.7%)
2/13
(15.4%)
1/13
(7.7%)
4/41 (9.8%)
  1 3/15
(20%)
1/13
(7.7%)
2/13 (15.4%) 6/41 (14.6%)
  2 4/15
(26.7%)
3/13
(23.1%)
5/13 (38.5%) 12/41 (29.3%)
  3 2/15
(13.3%)
2/13
(15.4%)
4/13 (30.8%) 8/41 (19.5%)
  >3 5/15
(33.3%)
5/13
(38.5%)
1/13
(7.7%)
11/41 (26.8%)
  Missing 0/15 2/15 3/16 5/46
Belief that cranberry can help symptoms
  Yes 10/15
(66.7%)
7/13
(53.9%)
8/13 (61.5%) 25/41 (61%)
  No 1/15
(6.7%)
0/13
(0%)
0/13
(0%)
1/41 (2.4%)
  Unsure 4/15
(26.7%)
6/13
(46.2%)
5/13 (38.5%) 15/41 (36.6%)
  Missing 0/15 2/15 3/16 5/46
Belief that symptoms can get better without 
antibiotics
  Yes 5/15
(33.3%)
1/13
(7.7%)
4/13 (30.8%) 10/41 (24.4%)
  No 4/15
(26.7%)
4/13
(30.8%)
2/13 (15.4%) 10/41 (24.4%)
  Unsure 6/15
(40%)
8/13
(61.5%)
7/13 (53.9%) 21/41 (51.2%)
  Missing 0/15 2/15 3/16 5/46
Group 1—immediate antibiotics alone (control); group 2—immediate antibiotics and immediate cranberry; group 3—immediate cranberry and 
delayed antibiotics.
N/A, not applicable; UTI, urinary tract infection.
Table 1 Continued
 on M
arch 25, 2021 by guest. P
rotected by copyright.
http://bm
jopen.bm
j.com
/
B
M
J O
pen: first published as 10.1136/bm
jopen-2020-046791 on 22 F
ebruary 2021. D
ow
nloaded from
 
8 Gbinigie O, et al. BMJ Open 2021;11:e046791. doi:10.1136/bmjopen-2020-046791
Open access 
electronic diaries were fully complete (table 2). There 
were no electronic diary failures necessitating the issue of 
paper diaries. A mean of 9.2 participants were recruited 
per month, which exceeded predicted recruitment of 
between four and eight participants each month. All GP 
practices who were invited to recruit to the trial agreed 
to participate (100%, 5/5), however, one GP practice 
withdrew prior to site opening as they predicted that they 
would no longer have capacity to support the trial.
Only one participant reported a side effect or problem 
related to consuming cranberry capsules in the electronic 
diary (table 2). Few participants reported experiencing 
problems completing the electronic diary (8.6%, 3/35) 
or rating their symptoms using the scale of 0–50 (11.4%, 
4/35).
Three participants were lost to follow- up (figure 1). 
Loss to follow- up was determined to have occurred when 
a participant did not make any electronic diary entries 
and it was not possible to contact them at the 2- week 
follow- up call.
Two participants withdrew from the study. One partici-
pant was consented and randomly assigned to immediate 
cranberry capsules with delayed antibiotics. As soon as 
she received this assignment, she decided to withdraw 
from the study and did not receive the cranberry capsules. 
Another participant was consented and also randomised 
to immediate cranberry and delayed antibiotics. The day 
after being enrolled, she emailed the trial team asking to 
be removed from the mailing list (links to the electronic 
diary were sent by email). In light of this, the chief investi-
gator withdrew the participant from the study.
Participants were able to provide free- text comments 
on the final day (day 14) of diary completion. Free- text 
boxes allowed women to provide general comments about 
the trial, as well as comments specifically about difficul-
ties using the electronic diary, difficulties using the rating 
scale and any problems related to consuming cranberry 
capsules. Fourteen women provided comments.
Some women provided general feedback, including 
being ‘happy to help’ with the study and finding the diary 
Figure 1 CONSORT diagram showing the flow of trial participants. *Group 1—immediate antibiotics alone (control); group 
2—immediate antibiotics and immediate cranberry capsules; group 3—immediate cranberry capsules and delayed antibiotics. 
CONSORT, Consolidated Standards of Reporting Trials.
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Table 2 Primary outcomes
Proportion (%), unless otherwise specified
Group 1
(n=15)
Group 2
(n=15)
Group 3
(n=16)
Total
(n=46)
Number of diaries with some data points entered by 
participant by end of participant follow- up
15
(100%)
13
(86.7%)
13
(81.3%)
41
(89.1%)
Number of diaries fully completed by participant by 
end of participant follow- up
13
(86.7%)
10
(66.7%)
9
(56.3%)
32
(69.6%)
Paper diaries issued due to failure of electronic diary 0
(0%)
0
(0%)
0
(0%)
0
(0%)
Number randomised as a proportion of the target 
recruitment number
46/45
(102.2%)
Number randomised as a proportion of invited 
participants
46/120
(38.3%)
Number randomised as a proportion of eligible 
participants
46/67
(68.7%)
  No of patients invited 120
  No of patients eligible 67
  No of participants enrolled 15 15 16 46
  No of participants randomised 15 15 16 46
  No of recruited per month (n) 9.2
Number of participants lost to follow- up 0
(0%)
2
(13.3%)
1
(6.3%)
3
(6.5%)
Number of participants withdrawing from study 0
(0%)
0
(0%)
2
(12.5%)
2
(4.4%)
Side effects or problems related to cranberry 
consumption
  Yes 0/13
(0%)
0/10
(0%)
1/11
(9.1%)
1/34 (2.9%)
  No 1/13
(7.7%)
10/10
(100%)
10/11 (90.9%) 21/34 (61.8%)
  Not applicable 12/13 (92.3%) 0/10
(0%)
0/11
(0%)
12/34 (35.3%)
  Missing 2/15 5/15 5/16 12/46
Problems completing the electronic diary
  No problem 14/14 (100%) 9/10
(90%)
9/11
(81.8%)
32/35 (91.4%)
  Some problems 0/14
(0%)
1/10
(10%)
2/11
(18.2%)
3/35 (8.6%)
  Lots of problems 0/14
(0%)
0/10
(0%)
0/11
(0%)
0/35
(0%)
  Missing 1/15 5/15 5/16 11/46
Problems using the scale of 0–50
  No problem 12/14 (85.7%) 9/9
(100%)
10/12 (83.3%) 31/35 (88.6%)
  Some problems 2/14 (14.3%) 0/9
(0%)
2/12
(16.7%)
4/35 (11.4%)
  Lots of problems 0/14
(0%)
0/9
(0%)
0/12
(0%)
0/35
(0%)
  Missing 1/15 6/15 4/16 11/46
Proportion of invited GP practices agreeing to 
participate in the trial
5/5
(100%)
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‘very easy to complete’. Two participants described some 
difficulty keeping up with filling in the diary ‘Just time and 
keeping up with it that is all. Happy to have taken part.’ 
(41-8, Immediate cranberry and delayed antibiotics). 
Another participant mentioned that she did not receive 
a link to complete the final set of diary questions, and 
one woman was unclear about the guidance regarding 
the need to continue completing the diary once symp-
toms had resolved for 2 consecutive days. Two women 
commented that the scale of 0–50 was ‘too wide a range’.
One woman stated that she was sceptical about cran-
berry at first, but found that it ‘helped a lot’ (32-11, Imme-
diate cranberry and delayed antibiotics). One participant 
found that the combination of antibiotic with cranberry 
cleared her infection ‘quite quickly’ (32-14, Immediate 
antibiotics and immediate cranberry), while another 
found that the antibiotic/cranberry combination resulted 
in her taking a shorter course of antibiotics than usual—
‘Nice to only take three days of antibiotics not a week’ 
(23-3, Immediate antibiotics and immediate cranberry). 
One woman stated that despite starting with cranberry, 
she had to take antibiotics on day 2 as she was in pain 
(41-2, Immediate cranberry and delayed antibiotics).
Three adverse events were picked up from free- text 
comments (see the Harms section below).
Secondary outcomes
Approximately one- third of respondents reported 
contacting a healthcare practitioner within 2 weeks of 
being enrolled (36.4%, 12/33). Most of these women 
contacted their GP practice (GP or nurse at their 
surgery)—one woman reported liaising with a pharma-
cist, and another contacted an out- of- hours GP. No partic-
ipants reported requiring Accident and Emergency or 
secondary care input. Just over half (54.3%, 25/46) of 
the urine samples at the time of enrolment were positive 
(organism growth greater than 10⁵/CFU (colony- forming 
unit)).
Exploratory analyses of effectiveness were conducted, 
while recognising that the study was not powered for 
these analyses (table 3). For this reason, p values have 
not been reported and any differences detected between 
groups are inconclusive.
There was a 20% reduction in the risk of consuming a 
course of antibiotics (or part thereof) in the immediate 
cranberry group (group 3), compared with the imme-
diate antibiotics alone group (group 1—controls). This 
was the case at both 2 weeks and 4 weeks (risk ratio 0.8; 
95% CI: 0.6 to 1.0). The number of courses of antibiotics 
consumed at 2 weeks and at 4 weeks was reduced in groups 
2 (immediate antibiotics and immediate cranberry) 
and 3 (immediate cranberry and delayed antibiotics), 
compared with the control group (adjusted incidence 
rate ratios: 0.7; 95% CI: 0.4 to 1.4 and 0.6; 95% CI: 0.3 to 
1.2 for group 2 and group 3, respectively). Participants 
in groups 2 and 3 had a longer duration of symptoms 
rated moderately bad or worse, compared with those in 
the control group (adjusted incidence rate ratios: 1.2; 
95% CI: 0.7 to 2.1 and 2.9; 95% CI 1.7 to 5.1 for group 2 
and group 3, respectively). The mean symptom burden 
(from day 2 to day 4 inclusive) was reduced in group 2 
participants (adjusted mean difference: 0.6; 95% CI: −4.0 
to 5.3) and increased in group 3 participants (adjusted 
mean difference: 7.9; 95% CI 2.6 to 13.2), compared with 
the control group. Similarly, the time to feeling recovered 
was reduced in group 2 (adjusted HR 1.7; 95% CI: 0.7 to 
4.1) but increased in group 3 (adjusted HR 0.6; 95% CI: 
0.2 to 1.4), compared with controls. Of women randomly 
assigned to take antibiotics alone (controls), one- third 
of respondents reported consuming cranberry products 
(33.3%, 4/12) (table 4).
An exploratory analysis was conducted to compare the 
proportion of participants experiencing ‘double sick-
ening’ between groups at 2 weeks. Double sickening was 
defined as a participant selecting the relevant checkbox 
in the electronic diary to confirm that they felt fully recov-
ered, then subsequently indicating through checkbox 
responses that they no longer felt fully recovered. Given 
the short period of time over which this was assessed (2 
weeks from enrolment), it is likely that these double sick-
ening episodes represent incompletely treated infection, 
rather than a new infection. Compared with the control 
group, group 2 participants had a reduced risk of expe-
riencing double sickening (risk ratio 0.6; 95% CI: 0.2 to 
2.0), while none of the group 3 participants experienced 
double sickening.
Proportion (%), unless otherwise specified
Group 1
(n=15)
Group 2
(n=15)
Group 3
(n=16)
Total
(n=46)
Proportion of invited GP practices opened and 
recruiting to the trial
4/5
(80%)
Acceptability of the study to participants and 
recruiters, participants’ experience of having a UTI 
and thoughts on self- help for UTIs
Interviews with trial participants and recruiters will be reported 
elsewhere.
Group 1—immediate antibiotics alone (control); group 2—immediate antibiotics and immediate cranberry; group 3—immediate cranberry and 
delayed antibiotics.
GP, general practitioner; UTI, urinary tract infection.
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Table 4 Secondary outcomes
Proportion (%), unless otherwise specified
Group 1
(n=15)
Group 2
(n=15)
Group 3
(n=16)
Total
(n=46)
Any of the following treatments used in the past 2 
weeks (not including study medication)
  Cranberry products
  Yes 4/12 (33.3%) 2/9
(22.2%)
2/9
(22.2%)
8/30 (26.7%)
  No 8/12 (66.7%) 7/9
(77.8%)
7/9
(77.8%)
22/30 (73.3%)
  Missing 3/15 6/15 7/16 16/46
  Other fruit juice
  Yes 0/12
(0%)
0/9
(0%)
0/9
(0%)
0/30
(0%)
  No 12/12 (100%) 9/9
(100%)
9/9
(100%)
30/30 (100%)
  Missing 3/15 6/15 7/16 16/46
  Bicarbonate solution
  Yes 0/12
(0%)
0/9
(0%)
0/9
(0%)
0/30
(0%)
  No 12/12 (100%) 9/9
(100%)
9/9
(100%)
30/30 (100%)
  Missing 3/15 6/15 7/16 16/46
  Sodium/potassium citrate (cystitis sachets)
  Yes 0/12
(0%)
0/9
(0%)
1/9
(11.1%)
1/30 (3.3%)
  No 12/12 (100%) 9/9
(100%)
8/9
(88.9%)
29/30 (96.7%)
  Missing 3/15 6/15 7/16 16/46
  Uvacin/uva ursi (bearberry)
  Yes 0/12
(0%)
0/9
(0%)
0/9
(0%)
0/30
(0%)
  No 12/12 (100%) 9/9
(100%)
9/9
(100%)
30/30 (100%)
  Missing 3/15 6/15 7/16 16/46
  Pain relief (eg, paracetamol/ibuprofen)
  Yes 5/12 (33.3%) 1/9
(11.1%)
5/9
(55.6%)
11/30 (36.7%)
  No 7/12 (58.3%) 8/9
(88.9%)
4/9
(44.4%)
19/30 (63.3%)
  Missing 3/15 6/15 7/16 16/46
  Other
  Yes 0/12
(0%)
0/9
(0%)
0/9
(0%)
0/30
(0%)
  No 12/12 (100%) 9/9
(100%)
9/9
(100%)
30/30 (100%)
  Missing 3/15 6/15 7/16 16/46
  None
  Yes 5/12 (41.7%) 6/9
(66.7%)
3/9
(33.3%)
14/30 (46.7%)
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Proportion (%), unless otherwise specified
Group 1
(n=15)
Group 2
(n=15)
Group 3
(n=16)
Total
(n=46)
  No 7/12 (58.3%) 3/9
(33.3%)
6/9
(66.7%)
16/30 (53.3%)
  Missing 3/15 6/15 7/16 16/46
Time off paid work or normal activities
  Yes 5/13 (38.5%) 2/10
(20%)
3/9
(33.3%)
10/32 (31.3%)
  No of days, median (IQR) 1
(1–2)
5
(2–8)
2
(1–2)
2
(1–2)
  No 8/13 (61.5%) 8/10
(80%)
6/9
(66.7%)
22/32 (68.8%)
  Missing 2/15 5/15 7/16 14/46
Healthcare professional consulted at GP practice
  Yes 6/13 (46.2%) 1/8
(12.5%)
5/12
(41.7%)
12/33 (36.4%)
  No 7/13 (53.9%) 7/8
(87.5%)
7/12
(58.3%)
21/33 (63.6%)
  Missing 2/15 7/15 4/16 13/46
  GP at surgery
  Yes 3/13 (23.1%) 0/8
(0%)
2/12
(16.7%)
5/33 (15.2%)
  No of times, median (IQR) 1
(1–1)
N/A 1
(1–1)
1
(1–1)
  No 3/13 (23.1%) 1/8
(12.5%)
3/12
(25%)
7/33 (21.2%)
  Not applicable 7/13 (53.9%) 7/8
(87.5%)
7/12
(58.3%)
21/33 (63.6%)
  Missing 2/15 7/15 4/16 13/46
  Nurse at surgery
  Yes 2/13 (15.4%) 1/8
(12.5%)
1/12
(8.3%)
4/33 (12.1%)
  No of times, median (IQR) 1
(1–1)
2
(2–2)
1
(1–1)
1
(1–1.5)
  No 4/13 (30.8%) 0/8
(0%)
4/12
(33.3%)
8/33 (24.2%)
  Not applicable 7/13 (53.9%) 7/8
(87.5%)
7/12
(58.3%)
21/33 (63.6%)
  Missing 2/15 7/15 4/16 13/46
  GP at home
  Yes 0/13
(0%)
0/8
(0%)
0/12
(0%)
0/33
(0%)
  No of times, median (IQR) N/A N/A N/A N/A
  No 6/13 (46.2%) 1/8
(12.5%)
5/12
(41.7%)
12/33 (36.4%)
  Not applicable 7/13 (53.9%) 7/8
(87.5%)
7/12
(58.3%)
21/33 (63.6%)
  Missing 2/15 7/15 4/16 13/46
  OOH doctor
Table 4 Continued
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Proportion (%), unless otherwise specified
Group 1
(n=15)
Group 2
(n=15)
Group 3
(n=16)
Total
(n=46)
  Yes 1/13
(7.7%)
0/8
(0%)
0/12
(0%)
1/33 (3.0%)
  No of times, median (IQR) 1
(1–1)
N/A N/A 1
(1–1)
  No 5/13 (38.5%) 1/8
(12.5%)
5/12
(41.7%)
11/33 (33.3%)
  Not applicable 7/13 (53.9%) 7/18
(87.5%)
7/12
(58.3%)
21/33 (63.6%)
  Missing 2/15 7/15 4/16 13/46
  Other
  Yes 0/13
(0%)
0/8
(0%)
2/12
(16.7%)—
pharmacist (1 
participant), 
phoned GP (1 
participant)
2/33 (6.1%)
  No of times, median (IQR) N/A N/A 1
(1–1)
1
(1–1)
  No 6/13 (46.2%) 1/8
(12.5%)
3/12
(25%)
10/33 (30.3%)
  Not applicable 7/13 (53.9%) 7/8
(87.5%)
7/12
(58.3%)
21/33 (63.6%)
  Missing 2/15 7/15 4/16 13/46
Healthcare professional consulted at A&E
  Yes 0/13
(0%)
0/10
(0%)
0/12
(0%)
0/35
(0%)
  No 13/13 (100%) 10/10
(100%)
12/12 (100%) 35/35 (100%)
  Missing 2/15 5/15 4/16 11/46
  No of times, median (IQR) N/A N/A N/A N/A
Seen by a specialist (excluding hospital admission)
  Yes 0/13
(0%)
0/10
(0%)
0/12
(0%)
0/35
(0%)
  No 13/13 (100%) 10/10
(100%)
12/12 (100%) 35/35 (100%)
  Missing 2/15 5/15 4/16 11/46
  No of times, median (IQR) N/A N/A N/A N/A
Admitted to hospital
  Yes 0/13
(0%)
0/10
(0%)
0/12
(0%)
0/35
(0%)
  No 13/13 (100%) 10/10
(100%)
12/12 (100%) 35/35 (100%)
  Missing 2/15 5/15 4/16 11/46
  No of nights, median (IQR) N/A N/A N/A N/A
Positive midstream urine culture
  Yes 10/15 (66.7%) 7/15
(46.7%)
8/16
(50%)
25/46 (54.3%)
  No 5/15 (33.3%) 8/15
(53.3%)
8/16
(50%)
21/46 (45.7%)
Table 4 Continued
Continued
 on M
arch 25, 2021 by guest. P
rotected by copyright.
http://bm
jopen.bm
j.com
/
B
M
J O
pen: first published as 10.1136/bm
jopen-2020-046791 on 22 F
ebruary 2021. D
ow
nloaded from
 
15Gbinigie O, et al. BMJ Open 2021;11:e046791. doi:10.1136/bmjopen-2020-046791
Open access
Proportion (%), unless otherwise specified
Group 1
(n=15)
Group 2
(n=15)
Group 3
(n=16)
Total
(n=46)
  Missing 0/15 0/15 0/16 0/46
Proportion with a positive midstream urine culture 54.3%
All outcomes reported in relation to the 2 weeks following trial enrolment.
Group 1—immediate antibiotics alone (control); group 2—immediate antibiotics and immediate cranberry; group 3—immediate cranberry and 
delayed antibiotics.
A&E, Accident and Emergency; GP, general practitioner; N/A, not applicable; OOH, out- of- hours.
Table 4 Continued
Table 5 List of adverse events
Adverse 
event 
number Group Adverse event Outcome Severity
Relationship 
to study 
product Comments
1 Immediate 
antibiotics 
alone
Tummy upset that 
started 3 days after 
starting ciprofloxacin 
(second course of 
antibiotics)
Resolved Mild Not related Not applicable
2 Immediate 
antibiotics 
alone
Reaction after taking 
one dose of antibiotic
Resolved Uncertain Not related Not applicable
3 Immediate 
antibiotics 
and 
immediate 
cranberry
Suprapubic pain, 
dysuria, backache, 
cloudy urine and single 
vomit
Resolved Moderate Possibly 
related
Possible pyelonephritis from 
description of symptoms, although 
not reported as such by healthcare 
practitioner. MSU positive—
Escherichia coli 10⁵ CFU/mL.
4 Immediate 
antibiotics 
and 
immediate 
cranberry
Vomiting after second 
course of nitrofurantoin 
started
Resolved Mild Possibly 
related
Vomit after second course of 
antibiotics started. Antibiotics 
stopped and participant 
encouraged to push fluids. 
Symptoms settled without further 
antibiotics being prescribed.
5 Immediate 
cranberry 
and delayed 
antibiotics
Feeling unwell, ache in 
lower back
Resolved Moderate Possibly 
related
Symptoms unlikely to be related 
to the study product, as the 
participant was recruited in the 
morning and the symptoms started 
the same day in the afternoon. 
Participant reported feeling fully 
recovered on day 2 and did not 
contact healthcare practitioner up 
to 28 days. MSU positive >E.coli 
10⁵ CFU/mL.
6 Immediate 
cranberry 
and delayed 
antibiotics
Felt sick Resolved Mild Possibly 
related
Participant mentioned that she 
was unsure whether the sickness 
symptom was related to cranberry 
or her UTI.
7 Immediate 
cranberry 
and delayed 
antibiotics
General feeling of 
being unwell, terrible 
backache and 
stomachache at times, 
headache and nausea
Resolved Moderate Possibly 
related
Possible pyelonephritis, however, 
no growth on MSU, reported 
feeling fully recovered on day 5, 
and the participant did not contact 
a healthcare practitioner up to 28 
days.
CFU, colony- forming unit; MSU, midstream urine; UTI, urinary tract infection.
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Harms
Seven adverse events occurred (table 5). Adverse events 
3 and 4 occurred in the same participant. Two adverse 
event descriptions sounded like possible pyelonephritis 
(numbers 3 and 7). However, one of these adverse events 
occurred in a participant whose midstream urine was nega-
tive, who reported feeling fully recovered on day 5 of the 
study and who did not contact a healthcare practitioner 
up to 28 days after enrolment. The second occurred in a 
participant who subsequently contacted her GP practice, 
however, her clinical syndrome was not reported as pyelo-
nephritis by the consulting healthcare practitioner and 
the participant’s symptoms settled with increased fluid 
intake alone. There were no serious adverse events.
The difference in the proportion of adverse events 
between groups was compared, although the feasibility 
trial was not powered to detect differences between 
groups. At 2 weeks, the point estimates indicated an 
increased risk of experiencing an adverse event for partic-
ipants in group 2 (risk ratio 1.2; 95% CI: 0.1 to 16.7) and 
group 3 (risk ratio 3.5; 95% CI: 0.4 to 29.4) compared 
with the control group, although the 95% CIs were wide. 
At 4 weeks, the risk of experiencing an adverse event in 
group 2 was lower than for the control group (risk ratio 
0.6; 95% CI: 0.1 to 5.7). The risk remained higher for 
participants in group 3 compared with controls at 4 weeks 
(risk ratio 1.7; 95% CI: 0.3 to 8.8) (online supplemental 
file 2).
DISCUSSION
In this open- label, feasibility randomised trial, we recruited 
beyond target and at a rate faster than predicted. Overall, 
participants found the trial procedures and interventions 
acceptable; few reported problems consuming cranberry 
capsules or using the electronic symptom diary.
Strengths and weaknesses
To our knowledge, this is the first trial to use cranberry 
capsules alone and combined with antibiotics as an acute 
treatment for UTI. The trial processes were designed, in 
discussion with PPI contributors, to be minimally burden-
some for participants and recruiters, which may have 
contributed to the faster than anticipated recruitment, 
and to recruiting beyond target.
Using a participant- completed diary led to missing 
data, and in particular, incomplete baseline data. We 
also collected very limited demographic data. Missing 
data means that we do not have a full picture of all of 
the participants’ experiences and outcomes. However, 
insights gained from the trial combined with the qualita-
tive interviews (to be reported elsewhere) should help to 
optimise future trial design and minimise missing data in 
a future study.
Some may describe the open- label design as a weak-
ness. However, this was designed to be a pragmatic trial 
with procedures closely aligned with real- world practice. 
We were therefore not prescriptive about the antibiotic 
issued, nor the duration, recognising that clinicians’ 
prescribing is influenced by a host of factors, including a 
patient’s medical history and UTI history. Despite this, we 
appreciate that there is a lack of standardisation of anti-
biotic prescribing between groups. Furthermore, partici-
pants who missed diary entries were able to complete the 
diary retrospectively; retrospective entries are likely to be 
less accurate than real- time diary completion.
We did not control participants’ consumption of 
other sources of PAC with type A linkages, namely blue-
berry. However, unless participants regularly consumed 
large amounts of blueberry, it is unlikely that this would 
have had a significant impact on the results. Interest-
ingly, despite advice not to, one- third of women in the 
immediate antibiotics alone group reported consuming 
cranberry products during the trial. This highlights the 
challenge of trying to control external influences in a 
trial, particularly when this is in conflict with a partici-
pant’s usual behaviour.
Comparison with the existing literature
No study participants developed pyelonephritis. A 
number of trials of non- antibiotic treatments have 
reported higher levels of pyelonephritis in participants 
not assigned to an antibiotic arm.3 5–7 The absence of 
cases of pyelonephritis in this trial may well have been 
due to the small sample size, but may also have resulted 
from all participants receiving a prescription for anti-
biotics, whether immediate or delayed antibiotics. In a 
trial of 382 women with uncomplicated UTIs evaluating 
the use of ibuprofen and the herbal extract uva ursi, all 
participants received delayed antibiotics and there were 
no cases of pyelonephritis.4
The proportion of participants lost to follow- up or with-
drawing from this feasibility trial (11%) is roughly compa-
rable with analogous trials, which report between 1.3%17 
and 16%.7 Of note, loss to follow- up is defined differently 
in different studies. The proportion of participants with a 
positive urine culture (54.3%) was lower than the propor-
tion reported in some analogous trials (range of 32%4–
80%17). Of note, this trial used a cut- off threshold for 
urine culture positivity of 10⁵ CFU/mL, while most other 
trials were aligned with European guidance and used a 
threshold of greater than 10² or 10³ CFU/mL.
While not powered to detect differences between 
groups, in line with the findings of similar trials, partic-
ipants in this feasibility trial not receiving immediate 
antibiotics (group 3) consumed fewer antibiotics but 
had a higher symptom burden. However, participants in 
group 3 were less likely to experience double sickening. 
Interestingly, Gagyor et al6 found that significantly fewer 
participants receiving ibuprofen compared with antibi-
otics experienced UTI recurrence between days 15 and 
28 (percentage mean difference −5.3% (95% CI: −10.2% 
to −0.4%), p=0.049). However, the difference between 
groups did not reach statistical significance when all 
recurrent UTIs from day 1 to day 28 were assessed 
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(percentage mean difference −2.8% (95% CI: −8.7% to 
3.1%), p=0.41).
A Cochrane review in 2012 found that overall, treat-
ment with cranberry did not significantly reduce recur-
rent UTIs (n=13 studies; risk ratio 0.86; 95% CI: 0.71 to 
1.04).18 This was also the case in a subgroup analysis 
that focused on women with UTI (n=4 studies; risk ratio 
0.74; 95% CI: 0.42 to 1.31). However, the review authors 
acknowledged that many included studies had high rates 
of participant withdrawal/loss to follow- up of up to 55%, 
largely attributed to difficulty adhering to drinking large 
volumes of cranberry juice on a daily basis. Furthermore, 
there was a lack of standardisation and poor reporting 
of the amount of cranberry extract—and specifically of 
PAC—in the interventions used. In this feasibility trial, 
we used cranberry capsules with a standardised amount 
of PAC, for short- term use in the context of acute UTI. 
These key differences may have contributed to better 
adherence of participants to the study intervention.
Implications for clinicians, researchers and policymakers
This feasibility trial was not powered to detect differences 
between groups, thus, no definite inferences about the 
effectiveness or safety of cranberry in the context of acute 
uncomplicated UTI can be made. If cranberry extract is 
found to be safe and effective in the management of acute 
UTIs through robust and adequately powered trials, it 
could represent an important health intervention for this 
common condition and has the potential to significantly 
reduce antibiotic consumption.
There is a need for adequately powered, randomised 
clinical trials to provide definitive evidence of whether 
cranberry extract is effective in reducing antibiotic use 
and managing symptoms of acute UTI. While this feasi-
bility trial does not provide evidence of the effectiveness 
or safety of cranberry extract in the context of acute 
UTI, the exploratory analyses suggest that it would be 
worthwhile to explore these as yet unanswered questions 
through an adequately powered trial. Such trials should 
use cranberry products with standardised amounts of 
PAC. Participants should be willing to stop all non- trial 
cranberry products for the duration of the study; as a 
minimum, the use of non- trial cranberry products by 
participants should be captured.
CONCLUSION
It is feasible to conduct a randomised trial of similar 
design to this study to assess whether cranberry extract 
can help reduce antibiotic use for symptoms of acute, 
uncomplicated UTI. The exploratory, underpowered 
analyses suggest that cranberry (alone and combined 
with antibiotics) may have a beneficial impact on certain 
measures of antibiotic usage and symptoms. These find-
ings support the conduct of further, definitive research 
in this area.
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